Lee Sung 4

What Happened
Lee Sung, Chief Financial Officer of Cytokinetics (CYTK), received annual equity awards on March 15, 2026: 20,646 restricted stock units (RSUs) and two stock-option grants totaling 31,145 options (1,665 and 29,480). The transactions are recorded as awards/grants (code A) at an acquisition price of $0.00 (i.e., compensation grants), so the Form 4 shows $0 cash change on acquisition. If all RSUs convert and options are exercised, the awards would represent up to 51,791 underlying shares.

Key Details

• Transaction date: 2026-03-15; Form 4 filed 2026-03-17 (no late filing indicated in the filing excerpt).
• Awards: 20,646 RSUs (F1); 1,665 options (F2); 29,480 options (F3). Reported acquisition price: $0.00 for each grant.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes/vesting:
  • F1 (RSUs): convert 1:1 to common shares; vest 40% at 1 year, additional 40% at 2 years, final 20% at 3 years, subject to continued employment and the 2004 Equity Incentive Plan.
  • F2/F3 (options): vest in 48 equal monthly installments, subject to continued employment and the 2004 Equity Incentive Plan.
• Transaction code: A = Award/Grant (not an open-market buy or sale).

Context
RSUs convert directly to shares when they vest; stock options are derivative securities that must be exercised (and may require payment of an exercise price) to become shares. Grants recorded at $0.00 are standard for equity compensation filings and reflect the grant event, not the market value realized. Such awards are part of routine executive compensation and do not by themselves indicate an immediate buy/sell signal.